Abstract
Recent studies have identified a stereospecific (+)-NANM binding site that binds psychotomimetic opioids and phencyclidine (PCP) but has a distribution in brain different from the PCP binding site. Since (+)-NANM has no opioid activity and (-)-NANM has opioid activity, rats were trained to discriminate (+)-NANM from saline in order to develop an ability to distinguish the (+)-NANM cues from other opioid agonist and antagonist activities. Cyclazocine, PCP, and ketamine all produced (+)-NANM-like stimuli in a dose-dependent manner. Behaviorally, cyclazocine and PCP are equipotent to (+)-NANM whereas ketamine is 6.7 times less potent than (+)-NANM. Pentazocine had the higest affinity for the (+)-[3H]NANM binding site, yet did not produce (+)-NANM-like discriminative stimuli. By contrast, ketamine had the lowest binding affinity for the (+)-[3H]NANM binding site and did produce (+)-NANM-like discriminative stimuli. Drug discrimination potencies relative to (+)-NANM were not predictive of relative binding affinities at (+)-NANM or PCP binding sites, although there was a trend toward a stronger correlation with the PCP binding site. Therefore, the discriminative stimulus properties of (+)-NANM cannot be explained by pharmacologic actions at either (+)-NANM or PCP binding sites alone, and may involve concurrent actions at both sites.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aceto MD, May EL (1983) Antinociceptive studies of the optical isomers of N-allylnormetazocine (SKF 10,047). Eur J Pharmacol 91:267–272
Balster RL, Brady KT (1982) Similarities in the discriminative stimulus properties of (+)-N-allylnormetazocine and phencyclidine in the rat. In: Colpaert FC, Slangen JL (eds) Drug Discrimination: Applications in CNS pharmacology, Elsevier Biomedical, Amsterdam, pp 99–108
Chau TT, Carter FE, Harris LS (1983) Antitussive effect of the optical isomers ofmu, kappa andsigma opiate agonists/antagonists in the cat. J Pharmacol Exp Ther 226:108–113
Contreras PC, Quirion R, O'Donohue TL (1985) Comparison of the binding and regional distribution ofsigma opioid and phencyclidine receptors. Soc Neurosci Abstr 11:583
Freeman AS, Bunney BS (1984) The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 104:287–293
Gundlach AL, Largent BL, Snyder SH (1985) Phencyclidine and σ opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol 113:465–466
Haertzen CA (1970) Subjective effects of narcotic antagonists cyclazocine and nalorphine on the addiction research center inventory (ARCI), Psychopharmacology 18:366–377
Holtzman SG (1980) Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther 214:614–619
Holtzman SG (1983) Discriminative stimulus properties of opioid agonists and antagonists. In: Cooper SJ (ed) Theory in psychopharmacology Vol. 2. Academic, New York, pp 2–45
Itzhak Y, Hiller JM, Simon EJ (1985) Characterization of specific binding sites for [3H](d)-N-Allylnormetazocine in rat brain membranes. Mol Pharmacol 27:46–52
Katz, JL, Spealman RD, Clark RD (1985) Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys. J Pharmacol Exp Ther 232:452–461
Keats AS, Telford J (1964) Narcotic antagonists as analgesics. Clinical aspects. Adv Chem Ser 45:170–176
Khazan N, Young GA, El-Fakahany EE, Hong O, Calligaro D (1984) Sigma receptors mediate the psychotomimetic effects of N-allylnormetazocine (SKF 10,047) but not its opioid agonist-antagonistic properties. Neuropharmacology 23:983–987
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS (1959) Study of a new schizophrenomimetic drug — sernyl. Arch Neurol Psychiatr 81:363–369
Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532
Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL (1984) Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther 231:539–544
Mendelsohn LG, Kalra V, Johnson BG, Kerchner GA (1985)Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor. J Pharmacol Exp Ther 233:597–602
Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D (1959) Comparison of serenyl with other drugs. Stimulation of schiziophrenic performance with serenyl, LSD-25, and amobarbital (amytal) sodium: 1. Attention, motor function, and proprioception. Arch Gen Psychiatry 1:651–656
Shannon HE (1982) Phencyclidine-like discriminative stimuli of (+)- and (-)-N-allylnormetazocine in rats. Eur J Pharmacol 84:225–228
Shannon HE (1983) Pharmacological evaluation of N-allylnormetazocine (SKF 10,047) on the basis of its discriminative stimulus properties in the rat. J Pharmacol Exp Ther 225:144–152
Shannon HE, Holtzman SG (1976) Evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 198:54–65
Shearman GT, Herz A (1982) Generalization and antagonism studies with rats trained to discriminate an effect of the proposedsigma opiate receptor agonist N-allylnormetazocine (SKF 10,047). In: Colpaert FC, Slangen JL (eds) Drug discrimination: Applications in CNS Pharmacology. Elsevier Biomedical, Amsterdam, pp 37–47
Siegel RK (1987) Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Peterson RC, Stillman RC (eds) Phencyclidine (PCP) abuse: an appraisal. NIDA, Washington, DC, pp 119–147
Slifer BL, Balster RL (1983) Reinforcing properties of stereoisomers of the putativesigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. J Pharmacol Exp Ther 225:522–528
Tallarida RJ, Murray RB (1981) Manual of pharmacologic calculations with computer programs. Springer, Berlin Heidelberg New York
Tam SW (1983) Naloxone-inaccessible σ receptor in rat central nervous system. Proc Natl Acad Sci USA 80:6703–6707
Tam SW, Cook L (1984) σ opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618–5621
Tam SW (1985) (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, μ, κ, δ and phencyclidine binding sites in guinea pig brain membranes. Eur J Pharmacol 109:33–41
Vaupel DB (1983) Naltrexone fails to antagonize the σ effects of PCP and SKF 10,047 in the dog. Eur J Pharmacol 92:269–274
Vignon J, Chicheportiche R, Chicheportiche M, Kamenka JM, Geneste P, Lazdunski M (1983) [3H]TCP: a new tool with high affinity for the PCP receptor in rat brain. Brain Res 280:194–197
Zukin SR, Zukin SR (1979) Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 76:5372–5376
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steinfels, G.F., Tam, S.W. & Cook, L. Discriminative stimulus properties of (+)-N-allylnormetazocine in the rat: Correlations with (+)-N-allylnormetazocine and phencyclidine receptor binding. Psychopharmacologia 91, 5–9 (1987). https://doi.org/10.1007/BF00690917
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00690917